| Autor: |
Israel, Debra S., Stotka, Jennifer, Rock, William, Sintek, Charles D., Kamada, Alan K., Klein, Catherine, Swaim, William R., Pluhar, Robert E., Toscano, John P., Lettieri, John T., Heller, Allen H., Polk, Ron E. |
| Zdroj: |
Clinical Infectious Diseases; 1996, Vol. 22 Issue 2, p251-256, 6p |
| Abstrakt: |
To detennine if ciprofloxacin therapy alters the response to warfarin treatment, 36 adult patients attending three university-affiliated outpatient anticoagulation clinics randomly received a 12-day course of ciprofloxacin (750 mg twice daily) and a 12-day course of placebo; each course was separated by a 2-week washout period. Prothrombin times (Pfs), concentrations of S-warfarin and R-warfarin (the isomers of warfarin), and concentrations of clotting factors IT and VII were determined three times weekly for 9 weeks. By day 12 of ciprofloxacin therapy, concentrations of S-warfarin remained unchanged compared with those after placebo therapy, but R-warfarin concentrations increased significantly (1.15 times those after placebo therapy; P = .001); concentrations of clotting factors IT and VII decreased (0.903 and 0.872 times those after placebo therapy, respectively, P ⩽ .020). The mean Pf ratio after 12 days ofciprofloxacin therapy increased slightly (1.032 times that after placebo therapy; P = .057), but no patient had bleeding or a change in Pf that required alteration in warfarin or ciprofloxacin therapy. We conclude that warfarin therapy is not a contraindication to the use of ciprofloxacin. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
